

Media Contact: Kim Tietz
SOLX Director Global Sales & Marketing
Ph: 215.380.4164
kim@solx.com

SOLX Receives Gold Shunt Clearance in Canada

Canadian physicians can now use Gold Shunt for the surgical treatment of Glaucoma without the need for special access approval

Waltham MA, July 8, 2009 – SOLX announced today that it has received clearance from Health Canada for the use of the SOLX Gold Shunt in the surgical treatment of glaucoma.

In a prospective, open label study with 12 months of follow-up using SOLX's GMS+ Gold Shunt, intraocular pressure (IOP) was reduced 45.6% from Best Medicated Baseline in patients that had failed maximum medical therapy and at least one prior surgical intervention.

Canadian ophthalmologist Paul Harasymowycz notes, "By harnessing the eye's natural pressure differential between the anterior chamber and the suprachroidal space, the SOLX Gold Shunt reduces IOP without creating a bleb, providing a new level of safety and control for glaucoma surgeons."

The SOLX Gold Shunt is biocompatible, 99.95% pure gold and provides a pathway for the flow of aqueous humor from the anterior chamber of the eye to the suprachoroidal space. The SOLX Gold Shunt preserves precious eye surface and the ability to perform future surgical interventions without a bleb.

The SOLX Gold Shunt family of devices joins the SOLX 790 Laser for Trabeculoplasty in products that have been cleared for sale in Canada. SOLX products are available in Canada from Innova Medical Ophthalmics with offices in Toronto and Montreal. They can be reached at 800.461.1200 or info@innovamed.com for more information on product availability.

ABOUT SOLX

Located in Waltham, MA, SOLX is a Glaucoma device company with a portfolio of products related to reducing, managing, and measuring IOP in the human eye. For additional information about SOLX products, please visit: www.solx.com.